drugset
drugset / Trial / NCT07153770

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

NCT07153770 ↗

Phase 2 Not yet recruiting 34 enrolled Shanghai Pulmonary Hospital, Shanghai, China
NaSingle-groupOpen-labelTreatment

Summary

This study aim to evaluate the efficacy and safety of Bozitinib combined with chemotherapy as radical treatment for stage IIA-IIIC MET-altered non-small cell lung cancer

Timeline

Start
2025-09-20
Primary completion
2027-09-20
Completion
2028-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Vebreltinib Small molecule — —

Indications

non-small cell lung carcinoma